4 February 2020 - The global Nanomedicine
Market size was worth USD 138.9
billion in 2016 which is anticipated to grow at a CAGR of more than 9.8% during
the forecast period. Factors such as technological advancements along with
significant applications in the prophylaxis of acute and chronic diseases,
prevention intervention, and early disease diagnosis are accountable for
progress of this industry. Miniaturization of bigger chemicals and structures
at nanometric scale enables the modernization in drug administration thus
leading to growth in nanotechnology market for healthcare industry.
Advancements
in nanorobotics due to the escalation in funding from the government bodies are
accountable to persuade potential to the nanomedicine market. Moreover,
nanorobotics engineering projects which are targeting only the cancer cells
without affecting the contiguous tissues is expected to promote progress
through to 2025.
Factors
such as the capability of nanotechnology to assist in both therapeutic and
diagnostics sector simultaneously are accountable for a large number of
researches which are undergoing in this sector. Moreover, application of DNA
origami in the healthcare is accountable for the projected CAGR.
Furthermore,
pipeline products based on the nano-molecules and related technologies are
expected to promote the progress over the forecast period. Other factors such
as, presence of number of products in phase II trial of clinical development
and personalized treatment option is also available which is accountable for
the development of nanotechnology for health care in the coming years.
Product Insights
In
2016, the foremost share was accounted by therapeutics owing to the existence
of various products such as drug delivery systems, devices, and drugs falling
in this classification. Number of therapeutic drugs that can be delivered
through nano methods is increasing with the inclination of pharmaceutical
companies towards these research activities.
Nanotechnology
is a promising technology which delivers drugs at the site of action with an
enhanced cellular penetration and reduced toxicity. The aforementioned fact, is
supportive for the estimated share of therapeutics segment. Moreover,
development of innovative delivery products by using various kinds of
nanoparticles is anticipated to boost the market growth.
Application Insights
Based
on application, the segment incorporates cardiology, infectious diseases,
oncology, and other applications. In 2016, oncology segment dominated with
approximately 47% revenue share.
Rise
in the R&D and funding activities in this segment is attributive for the
larger share of this segment. Moreover, continuous increase in the incidence of
oncology diseases is attributive for the development of nanotechnology based
products for cancer eradication.
Cardiology
is expected to witness fastest growth as a result of higher demand in the
projected period due to several opportunities such as implants for tissue
regeneration, nanostructured stents, and therapeutic nano-vectors.
Nanomolecule Type Insights
The
capability of nanoparticles to get linked with the chemical moieties in
different forms such as scaffolds aids in performing different functions.
Moreover, application of nanoparticles for active targeting by linking it to
cell receptor’s ligands is expected to drive progress potentially
nanotechnology.
Metal
and metal oxide is expected to witness substantial demand due to its widespread
utilization in diagnostics. These nanoparticles enable diagnosis through the
unique properties of different metals and metal oxides.
Dendrimers
and the inorganic nanoparticles are also anticipated to grow at a potential
rate in the coming years as consequence of research carried out in these
segments. Furthermore, rising inclination of physicians towards nanodevices for
monitoring and prognosis is anticipated to boost demand in the coming years.
Regional Insights
The
nanomedicine market was dominated by North America with over 42% of revenue
share due to escalating partnerships between nanomedicine startups and
enterprises. Moreover, assistance from government organizations along with
higher R&D expenditure is accountable for the largest share of the province
in this sector.
Asia
Pacific is anticipated to witness fruitful growth owing to factors such as
rising demand for prophylaxis of life-threatening diseases and increase in a
number of research grants. The escalation in a number of venture capital
financiers and rising international research associations are expected to
promote the nanomedicine growth in this region.
Competitive Insights
Several
vital players are functioning in this market such as Teva Pharmaceutical
Industries Ltd, Nanosphere, Inc., Celegene Corporation, Ablynx NV, GE
Healthcare, Arrowhead Research, and Combimatrix Corp. These players are engaged
in attaining the U.S. FDA approvals in order to enhance their revenue share.
Rising
penetration of the companies in diverse segments with respect to nanotechnology
in order to replace the conventional options of treatment and diagnosis is
anticipated to lead in growth in the coming years. Market entities are engaged
in collaborations with research institution and academic organizations in order
to carry out active research.
Market Segment:
Product Outlook (Revenue, USD Billion;
2013 - 2025)
• Therapeutics
• Regenerative medicine
• In-vitro diagnostics
• In-vivo diagnostics
• Vaccines
Application Outlook (Revenue, USD
Billion; 2013 - 2025)
• Clinical Oncology
• Infectious diseases
• Clinical Cardiology
• Orthopedics
• Others
Nanomolecule Type Outlook (Revenue, USD
Billion; 2013 - 2025)
• Nanoparticles
• Metal & Metal Oxide
Nanoparticles
• By Type
• Gold Nanoparticles
• Silver Nanoparticles
• Iron Oxide Nanoparticles
• Alumina Nanoparticles
• Gadolinium Oxide
Nanoparticles
• Others
• By Application
• In-vivo Imaging
• Targeted Drug Delivery
• Proton Therapy
• In-vitro assays
• Cell & Phantom
Imaging
• Liposomes
• Polymers & polymer drug
conjugates
• Hydrogel nanoparticles
• Dendrimers
• Inorganic nanoparticles
• Nanoshells
• Nanotubes
• Nanodevices
Regional Outlook (Revenue, USD Billion;
2013 - 2025)
• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• Asia Pacific
• Japan
• China
• Latin America
• Brazil
• Middle East and Africa (MEA)
• South Africa
Comments
Post a Comment